Lineage Cell Therapeutics Inc (LCTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $201.12M
Last updated: Nov 17, 2026 at 4:23 PM ET
Lineage Cell Therapeutics Inc (LCTX) Statistics
Lineage Cell Therapeutics (LCTX) has a market cap of $201.12M and an enterprise value of $174.66M. Its share count is up 10.51% from a year earlier. It holds $26.46M more cash than debt, 13.16% of its market cap.
Total Valuation
Enterprise value is 13.16% below the market cap, as cash exceeds debt.
| Market Cap | $201.12M |
|---|---|
| Enterprise Value | $174.66M |
| Latest price (Nov 17, 2026) | $0.82 |
Key Dates
The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 19.1x and 3.1x. Its year-end P/S ranged from 0.7x to 72.6x from 2016 to 2025.
| P/S Ratio | 19.1x |
|---|---|
| Forward P/S | 13.2x |
| P/B Ratio | 3.1x |
| P/TBV Ratio | 8.4x |
Enterprise Valuation
| EV / Earnings | 93.1x |
|---|---|
| EV / Sales | 16.1x |
Price Statistics
The stock is down 56.44% over 52 weeks and trades 17.17% below its 50-day average.
| Beta (1Y) | 1.27 |
|---|---|
| 52-Week Change | -56.44% |
| 1-Month Change | -14.05% |
| 3-Month Change | -25.55% |
| 6-Month Change | -31.76% |
| 5-Year Change | -56.14% |
| 10-Year Change | -68.94% |
| Total Return (1Y) | -56.44% |
| Total Return (5Y CAGR) | -19.02% |
| Max Drawdown (1Y) | -59.43% |
| Max Drawdown (3Y) | -73.91% |
| Sharpe Ratio (1Y) | -1.36 |
| Correlation with SPY (1Y) | 0.31 |
| 50-Day Average | $0.99 |
| 200-Day Average | $1.29 |
| 52-Week Range | $0.77 to $1.99 |
| RSI (14 Days) | 36.2 |
| Average Volume (20 Days) | 2.19M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.96x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 5.96x |
|---|---|
| Quick Ratio | 5.96x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on invested capital is -6.66% over the last 12 months, against a 5-year average of -55.21%.
| Return on Equity (ROE) | 2.80% |
|---|---|
| Return on Assets (ROA) | 1.87% |
| Return on Invested Capital (ROIC) | -6.66% |
| ROE (5Y Average) | -56.53% |
| ROA (5Y Average) | -28.01% |
| ROIC (5Y Average) | -55.21% |
| Asset Turnover | 0.11x |
| Receivables Turnover | 10.21x |
Scores
LCTX has an Altman Z-Score of -2.44, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -2.44 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $10.84M over the last 12 months is up 0.18% from the 12 months before.
| Revenue | $10.84M |
|---|---|
| Revenue Growth (YoY) | +0.18% |
| Gross Profit | $10.77M |
| Operating Income | -$30.38M |
| Pretax Income | $326.00K |
| Net Income | $1.88M |
| Reported EPS (TTM) | -$0.08 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 66.99% of the $100.11M in total assets.
| Cash and Equivalents | $26.50M |
|---|---|
| Total Debt | $39.00K |
| Net Cash | $26.46M |
| Net Cash Per Share | $0.10 |
| Working Capital | $39.76M |
| Shareholder Equity | $67.06M |
| Book Value Per Share | $0.27 |
| Tangible Book Value | $24.69M |
| Tangible Book Per Share | $0.10 |
| Total Assets | $100.11M |
| Total Liabilities | $34.17M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $636.00K of capital spending, operating cash flow left -$26.46M of free cash flow.
| Operating Cash Flow | -$25.82M |
|---|---|
| Capital Expenditures | $636.00K |
| Free Cash Flow | -$26.46M |
| FCF Per Share | -$0.10 |
| Depreciation and Amortization | $763.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -280.34%.
| Gross Margin | 99.34% |
|---|---|
| Operating Margin | -280.34% |
| Pretax Margin | 3.01% |
| Net Margin | 17.32% |
| FCF Margin | -244.15% |
| Gross Margin (5Y Average) | 90.04% |
Growth
Revenue fell 0.33% a year over 3 years.
| Revenue Growth (3Y CAGR) | -0.33% |
|---|---|
| Revenue Growth (5Y CAGR) | +51.46% |
| Book Value Per Share Growth (2Y CAGR) | -27.40% |
| Tangible Book Per Share Growth (2Y CAGR) | -48.61% |
Dividends and Yields
LCTX does not pay a dividend. Its free cash flow yield is -12.77%.
| FCF Yield | -12.77% |
|---|---|
| Buyback Yield | -11.63% |
| Shareholder Yield | -11.63% |
Peer Position
Against 6 similar companies, LCTX has the 3rd highest P/S.
P/S RatioPeer median 10.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +1.75%
| P/S Ratio | 19.1x vs 10.1x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +0.18% vs +1.75% median |
Analyst Forecast
Consensus estimates put revenue growth at 7.54% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +7.54% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LCTX
What is LCTX's market cap?
Lineage Cell Therapeutics has a market cap of $201.12M. Its enterprise value, which adds debt and subtracts cash, is $174.66M.
How many shares of LCTX are outstanding?
Lineage Cell Therapeutics has 252.91M shares outstanding. The count is up 10.51% from a year earlier.
Does LCTX pay a dividend?
No. Lineage Cell Therapeutics does not pay a dividend.
How much debt does LCTX have?
Lineage Cell Therapeutics has $39.00K of total debt and $26.50M of cash and equivalents, a net cash position of $26.46M.
LCTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors